Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 6/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 6/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 6/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7378916 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| Hydrochloric Acid SCHEMBL170802 | 0.99 | KDM4E (1.00) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL9298183 | 0.92 | MAPK14 (0.85) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| Hydrochloric Acid SCHEMBL11369989 | 0.92 | TDP1 (0.87) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL9436245 | 0.92 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL11503168 | 0.87 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL11502671 | 0.86 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL9748155 | 0.86 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL2842996 | 0.85 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL9435904 | 0.83 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | claimed |
| WO-2014122298-A1 | INTERLEUKIN-4 INHIBITORS FOR THE TREAMTENT OF NEUTROPENIA | Universität Zürich (CH) | 2014-08-14 | — | — | WO | claimed |
| EP-1196167-B1 | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions | LIPTON STUART A (US) | 2006-04-19 | — | — | EP | claimed |
| WO-1990015534-A1 | MONOKINE ACTIVITY INTERFERENCE | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-27 | — | — | WO | claimed |
| EP-0403251-A2 | Monokine activity interference | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | claimed |
| EP-0011111-B1 | 5-(4-PYRIDYL)-6-(4-FLUOROPHENYL)-2,3-DIHYDROIMIDAZO-(2,1-B)-THIAZOLE, PROCESS FOR ITS PREPARATION AND MEDICAL COMPOSITION | SMITHKLINE BECKMAN CORPORATION (US) | 1982-09-22 | — | — | EP | claimed |
| EP-0011111-A1 | 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition | SMITHKLINE BECKMAN CORPORATION (US) | 1980-05-28 | — | — | EP | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| US-20250304667-A1 | COMPLEMENT COMPONENT C5 ANTIBODIES | ALLERGAN INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | disclosed |
| EP-0011111-B1 | 5-(4-PYRIDYL)-6-(4-FLUOROPHENYL)-2,3-DIHYDROIMIDAZO-(2,1-B)-THIAZOLE, PROCESS FOR ITS PREPARATION AND MEDICAL COMPOSITION | SMITHKLINE BECKMAN CORPORATION (US) | 1982-09-22 | — | — | EP | disclosed |
| EP-0011111-B1 | 5-(4-PYRIDYL)-6-(4-FLUOROPHENYL)-2,3-DIHYDROIMIDAZO-(2,1-B)-THIAZOLE, PROCESS FOR ITS PREPARATION AND MEDICAL COMPOSITION | SMITHKLINE BECKMAN CORPORATION (US) | 1982-09-22 | — | — | EP | disclosed |
| EP-0011111-A1 | 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition | SMITHKLINE BECKMAN CORPORATION (US) | 1980-05-28 | — | — | EP | disclosed |
| EP-0011111-A1 | 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition | SMITHKLINE BECKMAN CORPORATION (US) | 1980-05-28 | — | — | EP | disclosed |
| EP-0011111-A1 | 5-(4-Pyridyl)-6-(4-fluorophenyl)-2,3-dihydroimidazo-(2,1-b)-thiazole, process for its preparation and medical composition | SMITHKLINE BECKMAN CORPORATION (US) | 1980-05-28 | — | — | EP | disclosed |
| US-4175127-A | ANTIARTHRITIC AGENTS | SMITHKLINE CORPORATION (US) | 1979-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK13 23/4885MAPK12 12/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | MAPK14 4665/4885MAPK13 4620/4885MAPK12 4476/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAPK14 2820/4885MAPK13 1694/4885MAPK12 1316/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK14 18/4885MAPK13 1/4885MAPK12 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.